# Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.

Source: https://onco.cc/trials/nct07407465/  
OnCo record `nct07407465` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of trastuzumab deruxtecan, capecitabine and bevacizumab (glioblastoma use) in colorectal cancer, run by Gruppo Oncologico del Nord-Ovest, now recruiting.

## Summary

Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer. is a phase 2, interventional study registered as NCT07407465 by Gruppo Oncologico del Nord-Ovest, with a registry enrolment figure of 42 participants, started 2025-10-20 and due to reach its primary completion in 2027-10-20. Interventions recorded: Trastuzumab-Deruxtecan (T-DXd); Capecitabine; Bevacizumab. Conditions listed: Colorectal Cancer; Colorectal Adenocarcinoma; Rectal Adenocarcinoma; Rectal Cancer, Adenocarcinoma; Rectal Cancer, Metastatic; Colon Cancer Metastatic; Colon Cancer Adenocarcinoma. Primary outcome: Overall Response Rate. Colorectal eligibility wording from the registry: "* Have histologically documented adenocarcinoma of the colon or rectum, which is initially metastatic or unresectable locally advanced". Sites: France, Germany, Italy, Spain. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: CHIMERA
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07407465
- Phase: 2
- Setting: Phase II Single Arm Study of Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer: the CHIMERA Study.
- Sponsor: Gruppo Oncologico del Nord-Ovest
- Enrolled: 42

## Sources

- ClinicalTrials.gov NCT07407465: https://clinicaltrials.gov/study/NCT07407465

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [Capecitabine](https://onco.cc/drugs/capecitabine/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07407465.json